Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2022-08-11 00:00:00 ET · period of report 2022-08-09 · accession 0001714899-22-000125 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-11 | 2022-08-09 | DNLI | Ho Carole | Chief Medical Off | A - Grant | $0.00 | +22.5K | 110.6K | +26% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-09 | A | A | 22,500 | $0.00 | 110,597 | D | — | — | (F1) Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on August 9, 2023 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider ofthe Issuer through each such date. (F2) Includes 110,187 restricted stock units. |